Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Collen

Showing results (651-660 of 715) with videos related to

Pageof 72
Sort By:
Circulation|March 1, 1991
Kistrin, a polypeptide platelet GPIIb/IIIa receptor antagonist, enhances and sustains coronary arterial thrombolysis with recombinant tissue-type plasminogen activator in a canine preparationT Yasuda, H K Gold, R C Leinbach, et al.
Journal of the American College of Cardiology|September 1, 1990
Comparative effects of aspirin, a synthetic thrombin inhibitor and a monoclonal antiplatelet glycoprotein IIb/IIIa antibody on coronary artery reperfusion, reocclusion and bleeding with recombinant tissue-type plasminogen activator in a canine preparationT Yasuda, H K Gold, H Yaoita, et al.
Journal of the American College of Cardiology|December 1, 1990
Lysis of plasminogen activator-resistant platelet-rich coronary artery thrombus with combined bolus injection of recombinant tissue-type plasminogen activator and antiplatelet GPIIb/IIIa antibodyT Yasuda, H K Gold, R C Leinbach, et al.
Circulation|September 17, 1998
Local adenovirus-mediated transfer of human endothelial nitric oxide synthase reduces luminal narrowing after coronary angioplasty in pigsO Varenne, S Pislaru, H Gillijns, et al.
Archivos Del Instituto De Cardiologia De Mexico|July 1, 1994
[Reperfusion in acute myocardial infarct. The Working Group in Myocardial Reperfusion. The International Society and Federation of Cardiology (ISFC)]R C Schlant, R A O'Rourke, D Collen, et al.
Circulation|April 1, 1989
Differential sensitivity of erythrocyte-rich and platelet-rich arterial thrombi to lysis with recombinant tissue-type plasminogen activator. A possible explanation for resistance to coronary thrombolysisI K Jang, H K Gold, A A Ziskind, et al.
Circulation|October 15, 1995
A randomized trial of recombinant staphylokinase versus alteplase for coronary artery patency in acute myocardial infarction. The STAR Trial GroupS Vanderschueren, L Barrios, P Kerdsinchai, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 11, 1996
Urokinase-type plasminogen activator is effective in fibrin clearance in the absence of its receptor or tissue-type plasminogen activatorT H Bugge, M J Flick, M J Danton, et al.
Lancet (London, England)|April 13, 1985
Randomised trial of intravenous recombinant tissue-type plasminogen activator versus intravenous streptokinase in acute myocardial infarction. Report from the European Cooperative Study Group for Recombinant Tissue-type Plasminogen ActivatorM Verstraete, R Bernard, M Bory, et al.
Journal of the American College of Cardiology|April 1, 1988
Detection of coronary artery reperfusion with creatine kinase-MB determinations during thrombolytic therapy: correlation with acute angiographyH D Garabedian, H K Gold, T Yasuda, et al.
Pageof 72

Showing results (651-660 of 715) with videos related to

Sort By:
Pageof 72
Circulation|March 1, 1991
Kistrin, a polypeptide platelet GPIIb/IIIa receptor antagonist, enhances and sustains coronary arterial thrombolysis with recombinant tissue-type plasminogen activator in a canine preparationT Yasuda, H K Gold, R C Leinbach, et al.
Journal of the American College of Cardiology|September 1, 1990
Comparative effects of aspirin, a synthetic thrombin inhibitor and a monoclonal antiplatelet glycoprotein IIb/IIIa antibody on coronary artery reperfusion, reocclusion and bleeding with recombinant tissue-type plasminogen activator in a canine preparationT Yasuda, H K Gold, H Yaoita, et al.
Journal of the American College of Cardiology|December 1, 1990
Lysis of plasminogen activator-resistant platelet-rich coronary artery thrombus with combined bolus injection of recombinant tissue-type plasminogen activator and antiplatelet GPIIb/IIIa antibodyT Yasuda, H K Gold, R C Leinbach, et al.
Circulation|September 17, 1998
Local adenovirus-mediated transfer of human endothelial nitric oxide synthase reduces luminal narrowing after coronary angioplasty in pigsO Varenne, S Pislaru, H Gillijns, et al.
Archivos Del Instituto De Cardiologia De Mexico|July 1, 1994
[Reperfusion in acute myocardial infarct. The Working Group in Myocardial Reperfusion. The International Society and Federation of Cardiology (ISFC)]R C Schlant, R A O'Rourke, D Collen, et al.
Circulation|April 1, 1989
Differential sensitivity of erythrocyte-rich and platelet-rich arterial thrombi to lysis with recombinant tissue-type plasminogen activator. A possible explanation for resistance to coronary thrombolysisI K Jang, H K Gold, A A Ziskind, et al.
Circulation|October 15, 1995
A randomized trial of recombinant staphylokinase versus alteplase for coronary artery patency in acute myocardial infarction. The STAR Trial GroupS Vanderschueren, L Barrios, P Kerdsinchai, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 11, 1996
Urokinase-type plasminogen activator is effective in fibrin clearance in the absence of its receptor or tissue-type plasminogen activatorT H Bugge, M J Flick, M J Danton, et al.
Lancet (London, England)|April 13, 1985
Randomised trial of intravenous recombinant tissue-type plasminogen activator versus intravenous streptokinase in acute myocardial infarction. Report from the European Cooperative Study Group for Recombinant Tissue-type Plasminogen ActivatorM Verstraete, R Bernard, M Bory, et al.
Journal of the American College of Cardiology|April 1, 1988
Detection of coronary artery reperfusion with creatine kinase-MB determinations during thrombolytic therapy: correlation with acute angiographyH D Garabedian, H K Gold, T Yasuda, et al.
Pageof 72